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Both the CTLA-4 pathway and regulatory T cells (Treg) are essential for the control of immune homeo-
stasis. Their therapeutic relevance is highlighted by the increasing use of anti-CTLA-4 antibody in tumor
therapy and the development of Treg cell transfer strategies for use in autoimmunity and transplantation
settings. The CTLA-4 pathway ﬁrst came to the attention of the immunological community in 1995 with
the discovery that mice deﬁcient in Ctla-4 suffered a fatal lymphoproliferative syndrome. Eight years
later, mice lacking the critical Treg transcription factor Foxp3were shown to exhibit a remarkably similar
phenotype. Much of the debate since has centered on the question of whether Treg suppressive function
requires CTLA-4. The ﬁnding that it does in some settings but not in others has provoked controversy and
inevitable polarization of opinion. In this article, I suggest that CTLA-4 and Treg represent comple-
mentary and largely overlapping mechanisms of immune tolerance. I argue that Treg commonly use
CTLA-4 to effect suppression, however CTLA-4 can also function in the non-Treg compartment while Treg
can invoke CTLA-4-independent mechanisms of suppression. The notion that Foxp3 and CTLA-4 direct
independent programs of immune regulation, which in practice overlap to a signiﬁcant extent, will
hopefully help move us towards a better appreciation of the underlying biology and therapeutic sig-
niﬁcance of these pathways.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Despite the selection processes applied to T cells during their
development in the thymus, T cells with the capacity to recognize
self-proteins nevertheless arise and populate the periphery. These
T cells have the potential to cause autoimmune diseases, but
generally do not because powerful peripheral tolerance mecha-
nisms keep them in check [1]. The archetypal example of pe-
ripheral tolerance is provided by regulatory T cells (Treg) that are
endowed with potent immunosuppressive capacity and whose
continued presence is essential to prevent catastrophic over-
activation of the immune system [2]. Equally critical for immune
regulation is the T cell inhibitory protein CTLA-4, deﬁciency of
which triggers lethal autoimmunity [3,4]. Although the CTLA-4
and Treg ﬁelds emerged independently, recent years have wit-
nessed a striking convergence of the two research areas. This
article seeks to present the historical context of these two areas,
explore their intersection and ﬁnally highlight some of the perti-
nent questions remaining in this ﬁeld.7433 1943.
All rights reserved.2. Control of T cell responses by CTLA-4
2.1. Costimulatory control of T cell activation
CTLA-4 is an inhibitory relative of the T cell costimulatory
molecule CD28. While CD28 signaling promotes T cell activation,
CTLA-4 serves an immunoregulatory function, suppressing the T
cell response [5]. Despite their opposing functions, both CD28 and
CTLA-4 interact with the same shared ligands CD80 (B7.1) and CD86
(B7.2)(reviewed in Ref. [6]). The superior afﬁnity of CTLA-4 for both
ligands [7] is balanced by its predominantly intracellular location
[8] contrasting with CD28 which is constitutively expressed at the
cell surface (see Fig. 1.). A diverse array of mechanisms has been
proposed to account for the inhibitory function of CTLA-4; these
include competing with CD28 for binding to their shared ligands,
downregulating ligand expression and transmitting inhibitory
signals. The molecular mechanisms of CTLA-4 function are not the
focus of this article and are extensively reviewed elsewhere [9e13].2.2. CTLA-4: a critical inhibitor of autoimmunity
Widespread recognition of the importance of the CTLA-4
pathway came about when mice deﬁcient in the Ctla4 gene were
Fig. 1. Cellular expression of CTLA-4 and Foxp3. CTLA-4 is a predominantly intracel-
lular protein that is constitutively expressed in Foxp3þ Treg and induced in conven-
tional T cells following activation. CTLA-4 and CD28 bind to shared ligands (CD80,
CD86) on antigen presenting cells. The Treg transcription factor, Foxp3, promotes
expression of CTLA-4 and other characteristicTreg markers such as CD25 while
inhibiting expression of cytokines such as IL-2.
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inﬁltration and death around 3wk of age [3,4]. Pathology resulted
from the unchecked expansion of T cells possessing a diverse and
unbiased TCR repertoire [14] and exhibiting reactivity against self
tissues. Disease appeared to be driven by the CD4 compartment
since depletion of CD4 T cells from birth effectively prevented
lymphadenopathy and tissue inﬁltration [15]. A large body of
subsequent work has conﬁrmed the CTLA-4 pathway as a key
arbiter in the choice between immunity and tolerance. Blockade of
CTLA-4 with antibodies was shown to exacerbate disease in various
mouse models of autoimmunity [16e18] and could even induce
autoimmune manifestations in normal mice including gastritis,
oophoritis, and mild sialoadenitis [19].
Consistent with the above observations, polymorphisms in the
Ctla4 locus have long been associated with autoimmunity [20e22]
and further variation within the same gene cluster (CD28, ICOS) is
likely to contribute to the net phenotype imparted by this region
[23]. Several isoforms of CTLA-4 exist [21,24e29] and their relative
expression levels may also inﬂuence CTLA-4-dependent immune
regulation.
2.3. CTLA-4 regulates the CD28 pathway
Several lines of evidence support the view that the biological
function of CTLA-4 is to control CD28 signaling. Blocking CD80 and
CD86with CTLA-4-Ig (thereby abrogating CD28 signaling) is known
to inhibit disease in Ctla4/mice [30,31]. Similarly mice that lack
CD80 andCD86 aswell as CTLA-4 (i.e. triple knockoutmice) showno
signs of the immune dysregulation associated with CTLA-4 deﬁ-
ciency [32,33]. The requirement for CD80/CD86 to drive disease in
Ctla4/mice reﬂects their engagement of CD28, sincemice lacking
both CD28 and CTLA-4 have no evidence of spontaneous T cell
activation and do not develop pathology [34]. An intriguing study
from the Singer laboratory delved deeper into this issue by probing
which regions of the CD28 cytoplasmic domain were required for
pathology in Ctla4/ mice [35]. The candidate regions under
investigationwere the “YMNM”motif (residues 170e173) known to
bind phosphoinositide 3-kinase (PI3K), Grb2 and Gads; the “N-ter-
minal proline” motif “PRRP” (residues 175e178) that binds Itk; andthe “C-terminal proline motif “PYAP” (residues 187e190) that as-
sociates with Lck, Fyn and Grb2. Strikingly this approach revealed
that disease mapped to the status of the CD28 C-terminal proline
motif. Ctla4/ mice expressing CD28 molecules with two single
pointmutations in thismotif remained completely healthy,whereas
mutations in other regions of the CD28 cytoplasmic domain did not
interrupt pathology. Collectively these studies provide strong evi-
dence that the role of CTLA-4 is to regulate CD28-dependent T cell
activation.
3. Control of T cell responses by Treg
3.1. Treg as essential immune regulators
The notion that the peripheral immune compartment is not
entirely self tolerant but is policed by cells with regulatory activity
has now been ﬁrmly incorporated into mainstream immunology.
Early work by the Powrie, Sakaguchi and Shevach groups showed
that cells with immunoregulatory activity could be identiﬁed on
the basis of their CD45 isoform usage [36], or their expression of
CD38 [37] or CD25 [38e41]. It is nowwell established that Treg are
essential for the maintenance of tolerance to self-tissues (particu-
larly those that announce their presence via secretory function) as
well as regulating responses to environmental antigens, tumor
antigens and infectious agents [42e44]. Treg have also been
implicated in maintaining tolerance to the fetus during pregnancy
[45e48] and the role of peripherally induced Treg may be partic-
ularly signiﬁcant in this context [49]. Multiple suppressive mech-
anisms can be invoked by Treg [50,51] permitting them to control a
broad range of target cell populations in different contexts.
3.2. Identiﬁcation of the Treg transcription factor Foxp3
A key landmark in the Treg ﬁeld was the identiﬁcation of the
transcription factor Foxp3 that plays a central role in directing the
regulatory program (see Fig. 1). This discovery arose from a
sequencing project [52] to determine the causal mutation in the
scurfy mouse, an animal presenting with a severe lymphoprolifer-
ative syndrome [53]. The Foxp3 gene was pinpointed as the culprit,
and it was shown that a frameshift mutation in scurfy mice resulted
in a product lacking the carboxy-terminal forkhead domain [52].
Crucially, the Sakaguchi [54], Rudensky [55] and Ramsdell [56]
groups then made the link between the CD25þ Treg population
and the immune-regulatory function of the Foxp3 gene. It was
demonstrated that Foxp3 expression was essentially conﬁned to
CD4þCD25þ cells and was responsible for the regulatory activity of
this subset. Accordingly, adoptive transfer of CD4þCD25þ T cells
fromwildtypemice could rescue the lymphoproliferative syndrome
in scurfy mice [55] and retroviral expression of Foxp3 in CD25 T
cells was shown to endow them with regulatory function [54,55].
Similarly, transgenic expression of Foxp3 permitted CD25 T cells,
and even CD8 T cells to acquire regulatory activity [56]. Consistent
with the large body of evidence obtained in mouse models, muta-
tions in the Foxp3 gene in humans are associated with defective
immune regulation, manifesting as a syndrome that has been
termed immune dysregulation polyendocrinopathy enteropathy X-
lined (IPEX) [57,58]. It is now well established that although some
features of the Treg program emerge prior to [59] or independently
of [60] Foxp3 expression, Foxp3 is nonetheless critical for enforcing
the regulatory phenotype. In thymic-derived Treg, Foxp3 is turned
on in developing thymocytes with the majority of Foxp3þ cells
being CD4þCD8 cells and residing in the medulla [61]. The
strength of TCR signaling, “translated” by induction of Nr4a nuclear
receptors [62] and CD28 co-stimulation [63] both contribute to
upregulation of Foxp3 intrathymically. However, expression of
Table 1
The Foxp3/ and CTLA-4/ phenotypes can be corrected by the presence of
wildtype cells. The effect of adoptive transfer of the indicated bonemarrow into rag-
deﬁcient recipients, alone or with additional cells, is shown (in terms of whether
recipients became sick or remained healthy). Note: Depending on the study, “Foxp3
deﬁcient bone marrow” refers to bone marrow frommice lacking the Foxp3 gene or
bone marrow from scurfy mice that have a frameshift mutation in the Foxp3 gene.
Foxp3-deﬁcient
bone marrow
CTLA-4/ bone
marrow
Alone Sick [82,83] Sick [82,85,87,111]
Plus wildtype bone marrow Healthy [82,83] Healthy [33,82,85e88]
Plus wildtype CD4þCD25þ cells Healthy [84] Healthy [87,111]
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mice [64] and ablation of Foxp3-expressing cells in adult mice (by
exploiting Foxp3-driven diphtheria receptor expression) causes
fatal autoimmunity [2], consistent with a requirement for contin-
uous Foxp3 expression for Treg function. Treg preferentially accu-
mulate in lymph nodes draining the tissues that express their
cognate self-antigen [65] and as a consequence the Treg repertoire
can vary considerably between different anatomical locations [66].
3.3. What does Foxp3 do?
The question of precisely what Foxp3 does to elicit the regula-
tory program has proved harder than expected to tease out. Anal-
ysis of Foxp3-bound genes has uncovered numerous targets
[67,68], however none fulﬁlled the “holy grail” criterion of
providing a convincing molecular explanation for Treg function.
Indeed the Foxp3 target genes appeared to comprise only around
6% of the Foxp3-dependent genetic program [67]. Recent analysis
suggests part of this puzzlemay be explained by the ability of Foxp3
to associate with a surprisingly large number of co-factors that may
broaden its functional potential. By ﬁshing with a biotin-tagged
Foxp3 protein in a T cell hybridoma, Rudra et al. were able to pull
out no less than 361 binding partners for Foxp3 [69]. Interestingly,
although these included some of the Foxp3-interacting proteins
that had previously been described (e.g. NFAT [70] Runx [71]), other
known binding-partners (e.g. Irf4 [72], Hif1a [73]) were not iden-
tiﬁed in this approach. This hints that contextual cues (e.g. activa-
tion stimuli, hypoxia) may inﬂuence the composition of the
proteins recruited to the Foxp3 complex [69]. Thus the transcrip-
tional program directed by Foxp3 is likely to depend on the cellular
environment in which it is expressed since this will dictate its in-
teractions with different co-factors. As a basic principle, this may
explain why historically not all attempts to confer regulatory
function by Foxp3 transduction have been successful [74,75] and
why B cells from Foxp3 transgenic mice fail to exhibit suppressive
function [56].
Intriguingly, a distinct subset of Foxp3-binding transcription
factors appears to play a particularly important role in supporting
its function. Fu and colleagues identiﬁed a “quintet” of transcription
factors (Eos, IRF4, GATA-1, Lef1 and Satb1) that appear to reinforce
the regulatory program by promoting Foxp3 occupancy of target
sites and enhancing its transcriptional activity [76]. In human Treg,
a novel Foxp3 interacting protein termed FIK (Foxp3-interacting
KRAB domain-containing protein) has recently been identiﬁed
that serves to couple Foxp3 with the chromatin-remodeling scaf-
fold protein KAP1 [77]. The interaction of Foxp3 with FIK and KAP1
was found to be particularly important for its ability to down-
regulate genes such as IL-2 and IFNg while it was not required for
Foxp3-dependent upregulation of CTLA-4 and CD25. Collectively
these studies suggest that molecular control of Foxp3-dependent
regulation is highly complex involving large numbers of interact-
ing cofactors and the capacity to integratemultiple contextual cues.
4. Intersection between Treg- and CTLA-4-mediated tolerance
4.1. Early convergence of the Treg and CTLA-4 ﬁelds
The similarity between the phenotype of CTLA-4-deﬁcient and
Foxp3-deﬁcient mice sparked immediate interest in whether these
two genes might function in a common pathway. In other words,
could the CTLA-4 pathway explain the regulatory function of
Foxp3þ Treg? Early indications of the overlap between CTLA-4 and
Treg came from careful analysis of the regulation of CTLA-4
expression during T cell responses to peptide in vivo [78]. In this
studyMetzler and colleagues identiﬁed a small population of CTLA-4þ cells inmice that had not been immunizedwith speciﬁc peptide.
They characterized this population as CD25þ and CD45RBlow and
speculated that CTLA-4 expression might represent a “common
denominator” underpinning the regulatory function of both CD25þ
cells and CD45RBlow cells [78].
Potential links between the Foxp3 and CTLA-4 programs were
also probed by testing whether CTLA-4 was absent from scurfy
mice or whether CTLA-4-deﬁcient animals lacked Treg. In both
cases, quite the opposite was observed; scurfy [52] or Foxp3-
deﬁcient [55] mice expressed at least as much CTLA-4, if not
more, than their wildtype counterparts and CTLA-4-deﬁcient mice
actually harbored an augmented Treg population [79e81]. Thus,
despite the tantalizing similarity between the phenotypes of mice
lacking either gene, Foxp3 was not required for CTLA-4 induction
and nor was CTLA-4 required for expression of Foxp3.4.2. Foxp3/ and CTLA-4/ phenotypes are corrected in the
presence of wildtype cells
Consistent with the ability of Foxp3þ cells to elicit dominant
regulation, the presence of wildtype cells has been shown to
abolish the scurfy phenotype in mixed bone marrow chimeras
[82,83]. In fact injection of 106 CD4þCD25þ cells was able to pre-
vent disease in Rag-deﬁcient recipients of scurfy bone marrow [84]
while transfer of 4  105 wildtype CD4þCD25þ cells directly into
1e2 day old scurfy mice can restore immune homeostasis [55]. As
expected, bone marrow cells from animals impaired in their ca-
pacity to generate Treg, as a result of Foxo1/Foxo3 deﬁciency, are
unable to prevent the scurfy phenotype in mixed chimeras [83].
The correction of Treg deﬁciency (i.e. the scurfy phenotype) by
the presence of wildtype cells could be viewed as entirely pre-
dictable, given the acknowledged role of this subset in eliciting cell-
extrinsic regulation. Far more surprising was the observation that
CTLA-4 deﬁciency could be compensated for in exactly the same
way, namely by the mixing of CTLA-4/ bone marrow with
wildtype bone marrow in chimeric mice (see Table 1). This obser-
vation was reported by Bachmann and colleagues who found that
rag/ mice reconstituted with CTLA-4/ bone marrow alone
died roughly 10 weeks later whereas those that also received
wildtype bone marrow remained completely healthy [85]. Even
more striking was the ﬁnding that the CTLA-4/ T cells in such
mixed chimeras showed no signs of activation, suggesting that
CTLA-4 expression on one T cell was able to control the activation
status of another T cell. Given that an inhibitory signal delivered via
the CTLA-4 receptor was then the favored model for CTLA-4 func-
tion, this result was initially bafﬂing. However, the bone marrow
chimera experiment has stood the test of time, proving remarkably
reproducible in the hands of numerous investigators [33,82,86e
88]. The simplest interpretation of these data is that CTLA-4 can
function cell-extrinsically; i.e. T cells do not themselves need to
express CTLA-4 to feel its force.
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dominant regulation in bone marrow chimeric mice, the Bluestone
group sought to determine whether these two genes had to be
expressed in the same cell for regulation to occur [82]. To this end,
bone marrow from scurfy mice or CTLA-4/ mice (also lacking
CD80 and CD86) was injected alone or as a 1:1 mix into rag/
recipients. For the ﬁrst 50 days after transfer, the survival curves
were indistinguishable between the 3 groups, with around 50%
mortality during this period. However, subsequently a fraction of
the animals receiving the mixed bone marrow showed a delayed
decline, even though they all eventually died. These data hint at the
ability of either Foxp3 or CTLA-4 (or both) to function independently
of one another. However the fact that all mice receiving the mix of
scurfy and CTLA-4/ bonemarrow died indicates that CTLA-4 and
Foxp3 must be co-expressed in the same cell for efﬁcient immune
regulation to ensue. These data nicely complement the observation
that transgenic overexpression of Foxp3 can delay lethality in CTLA-
4/mice, but canonly provide a temporary reprieve [56]. Together
the data strongly suggest that effective immune regulation requires
at least a subset of cells to co-express Foxp3 and CTLA-4.
4.3. Role for CTLA-4 in Treg function
Studies by the Powrie [89] and Sakaguchi [19] groups were the
ﬁrst to provide direct evidence that the CTLA-4 pathway could be
used to elicit Treg suppression. However, the ﬁeld was fraught with
conﬂicting data. Early work from the Shevach group suggested that
anti-CTLA-4 antibody failed to reverse Treg suppression in vitro
[41], and others generated similar data [90]. A subsequent follow-
up analysis by the Shevach group concluded that different prepa-
rations of anti-CTLA-4 antibody showed signiﬁcant variation in
their capacity to inhibit suppression [91]. In addition, interpretation
of the results was complicated by the ability of such antibodies to
augment conventional T cell proliferation [91], raising the possi-
bility that the treatment increased conventional T cell (Tconv)
proliferation rather than altering the extent of Treg suppression.
This caveat was elegantly side-stepped in two other studies where
anti-CTLA-4 Fab fragments were demonstrated to abolish sup-
pression even in settings in which the conventional T cells were
derived from CTLA-4/ mice (and therefore could not be the
target of the anti-CTLA-4 antibody) [19,31].
At face value, the above ﬁndings would appear to conclusively
demonstrate a critical role for CTLA-4 in Treg function in vitro.
However, this is not thewhole story since testing this hypothesis by
gene-deﬁciency has continued to produce conﬂicting results. Some
studies show clearly that CTLA-4 deﬁciency abrogates Treg function
in in vitro assays [81,88]. On the other hand, numerous reports have
demonstrated that Treg from CTLA-4/ mice retain suppressive
function in vitro [31,79,92e94]. In some cases the CTLA-4/ Treg
suppress marginally less efﬁciently than wildtype Treg [79,93]
mirroring the early observation that CTLA-4/ Treg showed
w50% suppression compared to the w95% suppression elicited by
their wildtype counterparts [19]. Interestingly, Tang and colleagues
found that even though CTLA-4/ Treg were capable of sup-
pression, the function of wildtype Treg was abrogated by anti-
CTLA-4 antibody. This suggests that wildtype Treg use CTLA-4 to
suppress but that compensatory mechanisms might develop in
animals genetically deﬁcient in the CTLA-4 pathway. The potential
for gene-deﬁcient animals to invoke compensatory pathways is
elegantly illustrated by the observation that dual deﬁciency in IL-10
and IL-35 results in a striking compensatory increase in TRAIL
(tnfsf10) expression and increased reliance on the TRAIL pathway
for in vitro suppression [95].
The discrepancies in CTLA-4 dependence of Treg suppression
in vitro hold true in human as well as mouse. For example in somestudies anti-CTLA-4 antibody failed to interrupt human Treg sup-
pression [96], while in others suppression was found to be largely
CTLA-4 dependent with a minor contribution from TGFb [97].
Supporting a role for CTLA-4 on Treg, depletion of CD25þ cells was
shown to abrogate the ability of anti-CTLA-4 antibody to augment
the proliferation of human T cells [98]. Thus, just like the analysis of
mouse Treg, evidence both for and against a role for CTLA-4 in Treg
function has been obtained in vitro using human cells. The most
likely explanation for these conﬂicting data is that variation in
assay conditions (APC type, strength of TCR stimulus... etc) has a
profound impact on the CTLA-4 dependency of suppression. In at
least two studies, CTLA-4/ Treg were demonstrated to work
in vitro yet lacked suppressive capacity in vivo [79,94] emphasizing
the potential limitations of in vitro suppressive assays; ultimately
their reductionist nature might permit redundant mechanisms to
compensate for CTLA-4 deﬁciency more readily than in more
complex in vivo situations.
There is nowoverwhelming evidence to support a role for CTLA-4
in the function of Treg in in vivo settings. A selection of this evidence
is presented in Table 2. The emergence of cell-extrinsic models of
CTLA-4 function [11e13] has provided amechanistic basis for its role
in the Treg compartment and a conceptual framework for interpre-
tation of the original bonemarrowchimera experiments. A key piece
in this puzzle has been provided by the demonstration that CTLA-4
can physically remove its ligands from antigen presenting cells by a
process of trans-endocytosis, affording a mechanism for Treg to
regulate CD28 stimulation of other T cells [99].
Experimental settings in which CTLA-4-deﬁcient Treg retain
suppressive function in vivo can also be found in the literature
[29,33,92] and serve as important reminders that alternative mech-
anisms can compensate for a lack of CTLA-4 in certain circumstances.
Overall, the data point to a key role for CTLA-4 in Treg function
although othermechanisms can sometimes substitute in its absence.
4.4. Role for CTLA-4 in the conventional T cell compartment
It has been clearly established that CTLA-4 can also function to
regulate T cell responses when expressed on conventional T cells.
Ironically, the general acceptance of this idea owes much to the
early experiments showing that CTLA-4 antibodies altered T cell
proliferation in vitro [100e103] that were performed prior to
widespread recognition of the Treg lineage. These experiments
were generally performed on whole CD4 T cells, rather than on
puriﬁed CD4þCD25 cells; with the beneﬁt of hindsight, it is likely
that many of the CTLA-4 effects demonstrated in these early studies
were actually a result of targeting CTLA-4 on the Treg population.
Nevertheless, evenwhen TCR transgenic systems have been used in
subsequent studies to rigorously select against the presence of Treg
it is clear that CTLA-4 can still function to regulate the magnitude of
conventional T cell responses. Extensive evidence supports the
function of CTLA-4 in the Tconv compartment [104e111], including
the demonstration that CTLA-4 regulates the Tconv response to
soluble antigen [104] and to tissue-derived neo-self antigen [105]
as well as modulating the capacity of Tconv to inﬁltrate antigen-
bearing tissues and cause destruction [108]. The ﬁnding that mice
lacking CTLA-4 only in Treg live longer than those lacking CTLA-4
systemically [81] also points to a functional role for CTLA-4 in the
conventional T cell population.
5. Overall perspectives
5.1. Why is Treg function CTLA-4-independent in some studies?
The demonstration that loss of CTLA-4 in the Treg compartment
is sufﬁcient to precipitate lethal autoimmunity [81] implies that
Table 2
Examples of studies in which CTLA-4 has been shown to contribute to Treg function.
CTLA-4/ Treg population tested Observation Reference
CD4þCD25þ cells Regulation of colitis by CTLA-4-sufﬁcient Treg was largely
abrogated by anti-CTLA-4 blocking antibody. Note:
CTLA-4/ Treg were shown to regulate in an IL-10-dependent
manner, suggesting other mechanisms can compensate in mice
lacking CTLA-4 since birth.
[33]
Foxp3-expressing cells Speciﬁc deletion of CTLA-4 in Treg (by expression of
Foxp3-driven Cre in CTLA-4-ﬂoxed mice) caused lethal T cell
mediated autoimmunity featuring lymphadenopathy,
splenomegaly and widespread tissue inﬁltration.
[81]
CD4þCD25þ cells DO11þCTLA4/rag/ Treg were unable to control autoimmune
pancreas destruction in an adoptive transfer model of diabetes.
Wildtype Treg bearing an identical speciﬁcity (DO11þrag/)
conferred 100% protection from disease.
[79]
CD4þCD25þ CD62hi cells
(from young Ctla4/ mice)
CTLA-4/ Treg failed to control colitis induced by T cell transfer
into rag/ recipients. Wildtype Treg conferred protection
from colitis.
[94]
CD4þCD25þ cells Injection of wildtype Treg but not conventional T cells
(CD4þCD25) signiﬁcantly prolonged the lifespan
of CTLA-4/ mice.
[80]
CD4þCD25þ cells Wildtype Treg completely prevented disease induced by
CTLA-4/ T cells in rag/ recipients, demonstrating that
expression of CTLA-4 in Treg is sufﬁcient for regulation, even
if conventional T cells lack CTLA-4.
[87]
CD4þCD25þ cells Treg from CTLA-4/ mice expressing CTLA-4 only in activated
conventional T cells (under the control of the IL-2 promoter)
failed to control colitis induced by CD4þCD25 cells in
rag/ recipients. Wildtype Treg conferred 100% protection.
[109]
CD4þCD25þ CD62hi cells CTLA-4þ/þ but not CTLA-4/ Treg reduced the inﬁltration of
antigen-speciﬁc effector T cells into the pancreas and prevented
the destruction of pancreatic tissue.
[108]
CD4þCD25þ cells (puriﬁed from
healthy mixed bone marrow
chimeras)
CTLA-4/ Treg failed to suppress inﬂammatory bowel disease
induced by T cell transfer into rag/ recipients (0/4 mice survived).
Recipients of wildtype Treg showed complete protection (4/4 mice survived).
[88]
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being so, it prompts the question; why don’t investigators uni-
formly identify a role for CTLA-4 in Treg function? Although
numerous studies report CTLA-4-dependent Treg function (see
Table 2), there are notable exceptions where Treg lacking CTLA-4
elicit effective suppression. In my view, there are three main is-
sues to consider in this regard; whether the response being tar-
geted is CD28-dependent, the tissue site and differentiation state of
the cells being regulated, and the nature of the Treg itself.
As emphasized earlier, the central biological role of CTLA-4 is to
regulate the CD28 pathway (potentially via ligand competition
[112] and ligand downregulation [99,113e115] although other
mechanisms are also plausible). It follows that T cell responses that
do not utilize CD28 costimulation would not be predicted to be
subject to CTLA-4-dependent regulation. Interestingly, a recent
study using BDC2.5 Treg found that CTLA-4-deﬁcient cells were just
as effective as their wildtype counterparts at regulating diabetes in
an adoptive transfer model [29]. However, the diabetes model
employedwas the CD28KO.NODmouse inwhich the diabetogenic T
cell response is, by deﬁnition, CD28-independent. Thus, the failure
to demonstrate CTLA-4-dependent immune regulation in this
setting is expected, given that competition for (or downregulation
of) CD86 and CD80 would not be predicted to alter the activation of
CD28-deﬁcient T cells. In contrast, in a different TCR-transgenic
diabetes model, CTLA-4 deﬁciency abrogated the ability of Treg to
control disease [79]. The latter model utilized CD28-sufﬁcient mice
and the diabetogenic T cell response is CD28-dependent in this
system (Wang and Walker, unpublished observation) providing a
potential explanation for this difference.
Regarding context of the response being regulated, suscepti-
bility to regulation via non-CTLA-4-based mechanisms may varydepending on the tissue site and differentiation state of the T cells.
In the gut, IL-10 production may represent a good alternative to
CTLA-4 in controlling errant T cell responses. Accordingly regula-
tion of colitis by wildtype Treg can be blocked by anti-CTLA-4
antibody, but CTLA-4-deﬁcient Treg can instead utilize IL-10 to
achieve regulation [33]. In the pancreas, on the other hand, IL-10
may be a less reliable inhibitor of T cell immunity. While IL-10
can inhibit diabetes under certain circumstances [116,117], trans-
genic expression of IL-10 in the pancreas can actually exacerbate
diabetes [118]. Thus, IL-10 produced by CTLA-4-deﬁcient Tregs
could conceivably be less effective at eliciting immunosuppression
in the pancreas. The stage of the immune response may also dictate
the relative efﬁcacy of different suppressive mechanisms since
preventing T cell priming and curbing fully-differentiated effectors
may be fundamentally different processes.
Regarding the nature of the Treg, there has been much interest
in recent years in the subdivision of Treg into subsets based largely
on their transcription factor expression [119e123] or anatomical
location [124,125]. Frequently the transcriptional proﬁle of a given
Treg subset is reported to parallel that of the effector T cell subset
targeted for control [126]. While there are other ways to interpret
these data [127], at face value the message is that Treg are not a
homogenous population. It follows that different subsets of Treg
could employ particular suppressive mechanisms to differing ex-
tents. The careful characterization of human Treg populations by
the Sakaguchi laboratory revealed that those expressing CD45RA
produce more TGFbwhile the CD45RA-negative subset bear higher
CTLA-4 expression and are capable of greater IL-10 production
[128]. Thus, the type or differentiation state of the Treg population
in question may inﬂuence the dominant mechanism of suppression
it employs.
Fig. 2. CTLA-4 and Foxp3 direct overlapping programs of immune regulation. A large
fraction of CTLA-4-dependent immune regulation involves the actions of CTLA-4 on
the Treg population; however CTLA-4 can also act on conventional T cells. Likewise,
CTLA-4 represents a major mechanism of Treg function, but Treg can also call on
numerous non-CTLA-4 based suppressive mechanisms.
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expressing Tconv have regulatory function?
If we accept that CTLA-4 can indeed function in both the Treg
and Tconv compartments, one question that arises is how do these
functions differ? Early models of CTLA-4 function were based on
the notion that this receptor delivers a negative signal [101e103],
and certainly many of my own papers were written from this
perspective [105,129,130]. However, more recently the concept has
emerged that CTLA-4 can function cell-extrinsically, indirectly
controlling the responses of T cells that do not in fact express it [13].
This begs the question of whether CTLA-4 functions one way in
conventional T cells (for example transducing negative signals to
inhibit their activation) and another way in Treg (for example
triggering ligand downregulation on antigen presenting cells
[99,115]). Recent ﬁndings have shed new light on this issue; sur-
prisingly, both the Allison laboratory [110] and my own group [111]
found that conventional T cells were able to use CTLA-4 in a cell-
extrinsic manner e essentially just like Treg do. Accordingly con-
ventional T cells expressing CTLA-4 were able to regulate the pro-
liferation of CTLA-4-deﬁcient conventional T cells in their midst.
Interestingly a microarray comparison of CTLA-4-sufﬁcient and
CTLA-4-deﬁcient conventional T cells revealed “no obvious signa-
ture of active negative regulation” in the former [110], suggesting
that even in conventional T cells, extrinsic mechanisms of CTLA4
function may be more important than the transmission of negative
signals.
If CTLA-4 functions the sameway inTregandTconv, andcandirect
a cell-extrinsic regulatory program, does this then blur the distinc-
tion between Tconv and Treg? In other words, are we now claiming
that all T cells are essentially regulatory T cells by virtue of their
ability to express CTLA-4? We recently explored this issue by
comparing the capacity of CTLA-4-sufﬁcient Tconv and CTLA-4-
sufﬁcient Treg to control the lymphoproliferative disease associ-
atedwith CTLA-4 deﬁciency [111].We took advantage of the fact that
disease can be transferred into rag/ recipients by injecting pe-
ripheral lymphocytes from CTLA-4/ animals [131]. We found that
even though co-transferred Tconv could express CTLA-4, they were
unable to prevent disease, with the recipient animals losing asmuch
weight as those receiving CTLA-4/ cells alone. In contrast co-
transferred Treg were highly effective at preventing disease and
the recipient animals did not lose weight. This disease model is
particularly aggressive, not least because the peripheral CTLA-4/
lymphocytes are already activated at the point of adoptive transfer.
To probe a little deeper we adapted the system by adoptively trans-
ferring CTLA-4/ bone marrow rather than peripheral lympho-
cytes. This invokes a slower, less severe disease in the rag/
recipients that we reasoned might be easier to control. Accordingly,
adoptively transferred CTLA-4-sufﬁcient Tconvwere able to partially
regulate disease in this setting leading to reduced weight loss, less
severe tissue inﬁltration and decreased activation of peripheral T
cells [111]. While this showed that Tconv-expressed CTLA-4 could
partially regulate disease, it should be emphasized that regulation
was modest compared to that invoked by CTLA-4-sufﬁcient Treg.
Recipients of the latter showed no weight loss (and instead gained
weight), they lacked tissue inﬁltration and control of peripheral Tcell
activation was far more profound. Taken together, the overriding
message is that although CTLA-4-sufﬁcient Tconv exhibit modest
suppressive capacity, Treg are far superior at eliciting regulation. This
likely reﬂects theirhigher level of CTLA-4 expression and the fact that
they express CTLA-4 constitutively, unlike Tconv that require a 2 day
window to upregulate this protein [100,101,132]. Furthermore, the
concommitant production of cytokines by conventional T cells, that
are silenced in Treg by Foxp3, may serve to counteract suppression.
Interestingly forced expression of CTLA-4 in activated T cells underthe IL-2 promoter was able to signiﬁcantly delay disease in CTLA-4-
deﬁcient mice [109]. Since IL-2 is induced rapidly upon T cell acti-
vation [133] early CTLA-4 induction may explain the superior ca-
pacity of these T cells to control disease, compared with Tconv that
naturally express CTLA-4 in mice selectively lacking CTLA-4 in Treg
[81]. The notion that Treg are the dominant population eliciting
CTLA-4-dependent regulation, and that CTLA-4 function in Tconv
plays a supplementary role, may explain the lack of complementa-
tion between scurfy and CTLA-4/ bone marrow [82] since Treg
mayneed tobepresent for theCTLA-4effects onTconv tobe revealed.6. Conclusion
Although the CTLA-4 and Foxp3 stories emerged independently
of one another, they are nonetheless inextricably entwined (see
Fig. 2). A large portion of CTLA-4-dependent immune regulation is
achieved via expression of this molecule in the Treg compartment.
Conversely Treg rely heavily, although by no means exclusively, on
CTLA-4 to elicit regulatory function. Appreciation of the signiﬁcant
functional overlap between Foxp3 and CTLA-4 driven regulatory
programs, and recognition of the cases where these pathways
diverge, will guide the future harnessing of these pathways in
therapeutic settings.7. Final comments
This review was written to honor Professor Abul Abbas who has
been a valuedmentor and friend tome for over a decade. It is part of
an issue which is devoted to Professor Abul Abbas and part of the
Journal of Autoimmunity’s recognition of truly distinguished im-
munologists who have contributed so much to our ﬁeld; previous
honorees have included Harry Moutsopoulos, Ian Mackay, Noel
Rose, Chella David and Pierre Youinou [134e136]. My initial studies
into both CTLA-4 and regulatory T cells emanated form work car-
ried out in Abul’s lab where I remember with great fondness my
time as a Wellcome Trust postdoctoral fellow. His warmth, open-
ness and generosity and his excitement over new data are things I
recall vividly. Abul’s ability to convey the essence of a seminar in a
single sentence and his unwavering grasp on the “big picture” are
things I will always admire. It’s a pleasure to be able to offer this
L.S.K. Walker / Journal of Autoimmunity 45 (2013) 49e57 55article in recognition of Abul’s great contribution to the ﬁeld of
immunology.Acknowledgments
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